A New NO-Releasing Nanoformulation for the Treatment of Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease which continues to carry an unacceptably high mortality and morbidity. The nitric oxide (NO) pathway has been implicated in the pathophysiology and progression of the disease. Its extremely short half-life and systemic effect...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Cardiovasc Transl Res
Autores principales: Mohamed, Nura A., Ahmetaj-Shala, Blerina, Duluc, Lucie, Mackenzie, Louise S., Kirkby, Nicholas S., Reed, Daniel M., Lickiss, Paul D., Davies, Robert P., Freeman, Gemma R., Wojciak-Stothard, Beata, Chester, Adrian H., El-Sherbiny, Ibrahim M., Mitchell, Jane A., Yacoub, Magdi H.
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer US 2016
Materias:
Correspondence
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4830862/
https://ncbi.nlm.nih.gov/pubmed/26960567
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12265-016-9684-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares